Drug Discovery

Chondrial Therapeutics secures $22.6m in Series A financing

Biotechnology company Chondrial Therapeutics, focused on the treatment of rare mitochondrial diseases, has secured up to $22.6m in Series A financing led by Deerfield Management besides naming a new president and CEO in Carole Ben-Maimon, MD.

Soligenix’s SGX301 secures PIM status from UK MHRA to treat cutaneous T-cell lymphoma

Soligenix has secured Promising Innovative Medicine (PIM) designation from the UK Medicines and Healthcare Products Regulatory Agency for SGX301 (synthetic hypericin) to treat cutaneous T-cell lymphoma (CTCL).

Tarveda Therapeutics completes $30m Series D equity financing

Tarveda Therapeutics has raised $30m in series D financing to advance pentarin miniaturized drug conjugates.

Neurotrope signs licensing deal for accelerated synthesis of Alzheimer’s drug Bryostatin-1

Neurotrope has signed a licensing agreement with Stanford University for an accelerated synthesis of Alzheimer's drug bryostatin-1.

Biscayne Neurotherapeutics raises $3m for antiepileptic compound

Biscayne Pharmaceuticals has raised financing for its new spin-out, Biscayne Neurotherapeutics, which was recently established to develop its biopharmaceutical assets for the treatment of neurological disorders.

Cellestia Biotech raises CHF8m seed financing

Cellestia Biotech has raised CHF8m in funding from private investors and PPF Group to advance its lead anti-cancer compound CB-103 to clinical development stage.

Connect secures $25m financing to advance immune modulators clinical development

Connect Biopharmaceuticals has completed a $20m Series A financing to advance clinical development of novel immune modulators.

Discuva secures Innovate UK grant for new antibiotics development

Innovate UK has awarded a £1.5m Biomedical Catalyst early-stage award to drug discovery firm Discuva for the development of novel antibiotics to tackle the issue of multidrug-resistance and life-threatening bacterial infections.

Cue Biopharma raises $26M in funding

Cue Biopharma has announced a total of $26m of invested private capital, led by MDB Capital Group, to develop next-generation biologics to selectively control T Cell activity.